Directly from EULAR 2024: Study Reveals Romosozumab, Denosumab Effectively Treats RA Complicated with Osteoporosis
Treatment with romosozumab or denosumab among patients with either primary osteoporosis or rheumatoid arthritis (RA) complicated with osteoporosis (RA-OP) demonstrated clinical efficacy over separate 12-month treatment periods, according to a prospective cohort study presented at the 2024 European Congress of Rheumatology (EULAR). Investigators believe these treatments have the high potential to be important options in the treatment of RA-OP.
“Romosozumab, a monoclonal antibody that binds sclerostin, increases bone formation and decreases bone resorption,” wrote lead investigator Yasuhide Kanayama, MD, PhD, associated with the Department of Orthopedic Surgery and Rheumatology at Toyota Kosei Hospital, in Japan. “Although it is a novel therapeutic agent for osteoporosis, [it] has shown high effects of increasing bone density and inhibiting fragile fracture in overseas clinical trials. However, the clinical efficacy for RA complicated with osteoporosis is unknown.”
Source: MDMag
To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.
